4-(1-甲基乙基)-1-哌嗪甲脒 | 85063-72-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 4-(1-甲基乙基)-1-哌嗪甲脒
• 英文名称: 4-(Propan-2-yl)piperazine-1-carboximidamide
• 英文别名: 4-propan-2-ylpiperazine-1-carboximidamide
• CAS: 85063-72-5
• 化学式: C₈H₁₈N₄
• 分子量: 170.26
• InChiKey: WLQWTDSLRYOIHJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  56.4
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• Pyridine Compounds and the Uses Thereof
  申请人：NI Chiyou

  公开号：US20130303526A1

  公开（公告）日：2013-11-14

  The invention relates to substituted pyridine compounds of Formula (I) and the pharmaceutically acceptable salts, prodrugs, and solvates thereof, wherein R 1a , A 1 , A 2 , E, G, Z 1 , and Z 2 are defined as set forth in the specification. The invention is also directed to the use of compounds of Formula I to treat a disorder responsive to the blockade of sodium channels. Compounds of the present invention are especially useful for treating pain.

  本发明涉及式（I）的取代吡啶化合物及其药学上可接受的盐、前药和溶剂化物，其中R1a、A1、A2、E、G、Z1和Z2如规范中所述。本发明还涉及使用式（I）的化合物治疗对钠通道阻滞有反应的疾病。本发明的化合物特别适用于治疗疼痛。
• SUBSTITUTED PYRIDINES AS SODIUM CHANNEL BLOCKERS
  申请人：Purdue Pharma L.P.

  公开号：US20150045397A1

  公开（公告）日：2015-02-12

  The invention relates to substituted pyridine and pyrimidine compounds of Formula (I) and the pharmaceutically acceptable salts, prodrugs, and solvates thereof, wherein R 1 , R 2a , R 2b , A 1 , A 2 , X, and Z are defined as set forth in the specification. The invention is also directed to the use of compounds of Formula (I) to treat a disorder responsive to the blockade of sodium channels. Compounds of the present invention are especially useful for treating pain.

  本发明涉及式(I)的取代吡啶和嘧啶化合物及其药学上可接受的盐、前药和溶剂化物，其中R1、R2a、R2b、A1、A2、X和Z的定义如规范中所述。本发明还涉及使用式(I)的化合物治疗对钠通道阻滞响应的疾病。本发明的化合物特别适用于治疗疼痛。
• PYRIDINE COMPOUNDS AND THE USES THEREOF
  申请人：Purdue Pharma L.P.

  公开号：US20150259293A1

  公开（公告）日：2015-09-17

  The invention relates to substituted pyridine compounds of Formula (I) and the pharmaceutically acceptable salts, prodrugs, and solvates thereof, wherein R 1a , A 1 , A 2 , E, G, Z 1 , and Z 2 are defined as set forth in the specification. The invention is also directed to the use of compounds of Formula I to treat a disorder responsive to the blockade of sodium channels. Compounds of the present invention are especially useful for treating pain.

  本发明涉及式(I)的取代吡啶化合物及其药学上可接受的盐、前药和溶剂化物，其中R1a、A1、A2、E、G、Z1和Z2如规范中所述。本发明还涉及使用式(I)的化合物来治疗对钠通道阻滞有反应的疾病。本发明的化合物特别适用于治疗疼痛。
• Functionally-modified oligonucleotides and subunits thereof
  申请人：Sarepta Therapeutics, Inc.

  公开号：US10344281B2

  公开（公告）日：2019-07-09

  Functionally-modified oligonucleotide analogues comprising modified intersubunit linkages and/or modified 3′ and/or 5′-end groups are provided. The disclosed compounds are useful for the treatment of diseases where inhibition of protein expression or correction of aberrant mRNA splice products produces beneficial therapeutic effects.

  本研究提供了功能修饰的寡核苷酸类似物，这些类似物包含修饰的亚基间连接和/或修饰的 3′和/或 5′末端基团。所公开的化合物可用于治疗抑制蛋白质表达或校正异常 mRNA 剪接产物产生有益治疗效果的疾病。
• Indole derivatives and use thereof
  申请人：Purdue Pharma L.P.

  公开号：US10730866B2

  公开（公告）日：2020-08-04

  The Invention provides indole derivatives of Formula I: and pharmaceutically acceptable salts and solvates thereof, wherein R1e, R1f, A, X, Y, Z, and W4 are defined as set forth in the specification. The Invention also provides the use of compounds of Formula I and the pharmaceutically acceptable salts and solvates thereof to treat pain. In certain embodiments, the Compounds of the Invention are effective in treating a disorder responsive to blockade of one or more sodium channels.

  本发明提供了式 I 的吲哚衍生物：及其药学上可接受的盐和溶液，其中 R1e、R1f、A、X、Y、Z 和 W4 的定义如说明书所述。 本发明还提供了式 I 化合物及其药学上可接受的盐和溶解物治疗疼痛的用途。 在某些实施方案中，本发明的化合物对治疗一种或多种钠通道阻断反应性紊乱有效。